Meribank Biotech Co (ROCO:4724) Marketable Securities: NT$131.9 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4724 Meribank Biotech Co Ltd ROCO:4724
40 GF Score
Price NT$8.62
GF Value NT$49.52
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Meribank Biotech Co Marketable Securities?

Meribank Biotech Co ROCO:4724 +0.23% 40 Marketable Securities is NT$131.9 Mil as of Dec. 2025. GuruFocus rates ROCO:4724 with a GF Score™ of 40/100 and a GF Value™ of NT$49.52 (Possible Value Trap). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Meribank Biotech Co's Marketable Securities for the quarter that ended in Dec. 2025 was NT$131.9 Mil.

Meribank Biotech Co's annual Marketable Securities stayed the same from Dec. 2023 (NT$0.0 Mil) to Dec. 2024 (NT$0.0 Mil) but then increased from Dec. 2024 (NT$0.0 Mil) to Dec. 2025 (NT$131.9 Mil).

Meribank Biotech Co  (ROCO:4724) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Meribank Biotech Co Marketable Securities Related Terms

Meribank Biotech Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Meribank Biotech Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Meribank Biotech Co Marketable Securities Chart

Meribank Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 94.10 122.70 0.00 0.00 131.90

Meribank Biotech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 100.00 0.00 0.00 131.90
ROCO:4724
40GF Score
Meribank Biotech Co Ltd ROCO:4724
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Meribank Biotech Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of NT$131.9 Mil mean?
Meribank Biotech Co (ROCO:4724) has a Marketable Securities of NT$131.9 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Meribank Biotech Co and its competitors.
Is Meribank Biotech Co's Marketable Securities too high?
Meribank Biotech Co's current Marketable Securities is NT$131.9 Mil. Overall, Meribank Biotech Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Meribank Biotech Co's Marketable Securities compare to VRTX and REGN?
Meribank Biotech Co's Marketable Securities of NT$131.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Meribank Biotech Co and its competitors. Meribank Biotech Co's current Marketable Securities is NT$131.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meribank Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Meribank Biotech Co (ROCO:4724) is currently considered Possible Value Trap. The stock's GF Value™ is NT$49.52, compared to a current price of NT$8.62 — trading 82.6% below its estimated fair value. The current Marketable Securities is NT$131.9 Mil. Meribank Biotech Co's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Meribank Biotech Co (ROCO:4724), the current Marketable Securities is NT$131.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Meribank Biotech Co (ROCO:4724) Overvalued in 2026?

Based on GuruFocus' analysis, Meribank Biotech Co stock appears to be undervalued. The current stock price of NT$8.62 is trading 82.6% below its estimated GF Value™ of NT$49.52. GuruFocus considers Meribank Biotech Co to be Possible Value Trap.

Key valuation signals for ROCO:4724:

  • Marketable Securities: NT$131.9 Mil
  • GF Value™: NT$49.52 vs. price of NT$8.62 (82.6% below fair value)
  • GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the ROCO:4724 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Meribank Biotech Co Business Description

Address Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.
40GF Score

Get the complete analysis for ROCO:4724

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$8.62
Price
NT$49.52
GF Value